BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beqalzi (Sonrotoclax) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Beqalzi (Sonrotoclax)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: A Phase 1b/2 Study o
 f Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With 
 Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\, and Dexa
 methasone Plus Pomalidomide in Multiple Myeloma\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04973605
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06637501-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06637501)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Ver
 sus Zanubrutinib Alone in Participants With Previously Untreated Chronic L
 ymphocytic Leukemia\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06637501
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855991-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270208
DTEND;VALUE=DATE:20270209
SUMMARY:Beqalzi (Sonrotoclax): Phase 1 readout est. (NCT07855991)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1.\nStudy: A Study to Investigate
  the Safety\, Tolerability\, and Pharmacokinetics of Sonrotoclax in Partic
 ipants With Severe Hepatic Impairment\nEstimated primary completion: 8 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7855991
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07674810)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotoclax\
 , And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic 
 Leukemia\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04277637-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Beqalzi (Sonrotoclax): Phase 1 readout est. (NCT04277637)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1.\nStudy: Study of Bcl-2 Inhibit
 or Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
 \nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04277637
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07548710)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Study of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primar
 y completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sonrotoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07548710
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04271956-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT04271956)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Efficacy and Safety of
  Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for 
 Patients With Richter Transformation\nEstimated primary completion: August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042719
 56
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687004-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07687004)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: Sonrotoclax and BCMA
  Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t
 (11\;14) Genetic Stratification\nEstimated primary completion: 1 August 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07687004
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638787-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07638787)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: Pola-R-CHP Plus Sonr
 otoclax in Untreated BCL2-High/Double-Hit LBCL\nEstimated primary completi
 on: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sonrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07638787
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497062-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06497062)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatme
 nt of Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion
 : 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/so
 nrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06497062
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885397-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07885397)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: Sonrotoclax Plus Aza
 citidine in Patients With MDS-IB2\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0788
 5397
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671378-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07671378)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-
 Naïve\, High-Risk CLL/SLL Patients\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671378
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335887-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07335887)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Sonrotoclax Plus Dexam
 ethasone With or Without Daratumumab Regimen in Patients With t(11\;14) Pr
 imary AL Amyloidosis\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07335887
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06849713)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\, 
 Obinutuzumab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06849713
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants With 
 Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle Cel
 l Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812246-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07812246)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chroni
 c Lymphocytic Leukemia /Small Lymphocytic Leukemia\, ZeuS-2 Trial\nEstimat
 ed primary completion: 13 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07812246
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of BGB-11417 in Participants With Myeloid Malignancies\nEstim
 ated primary completion: 31 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742996-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06742996)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Mantle Cell Lymphoma.\nStudy:
  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubr
 utinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Ref
 ractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)\nEstimated primary completi
 on: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06742996
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799220-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07799220)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  A Study of Zanubrutinib\, Obinutuzumab\, and Sonrotoclax in People With M
 antle Cell Lymphoma\nEstimated primary completion: September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07799220
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932873-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Beqalzi (Sonrotoclax): Phase 2/3 readout est. (NCT07932873)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2/3.\nStudy: Sonrotoclax in Combi
 nation With Azacitidine for Previously Untreated Higher-risk Myelodysplast
 ic Syndromes\nEstimated primary completion: 1 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07932873
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321652-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT07321652)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: Testing the Addition of Anti-Cancer Drug Sonrotoclax\, to the Sta
 ndard Treatment Zanubrutinib\, for Previously Untreated CLL/SLL\nEstimated
  primary completion: 30 September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07321652
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463691-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06463691)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Sonrotoclax\, Zanubrut
 inib and CD20mab in Untreated MCL Patients\nEstimated primary completion: 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrot
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06463691
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634589-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281202
DTEND;VALUE=DATE:20281203
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06634589)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: A Study to Investiga
 te Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination Wit
 h Other Agents in Participants With Relapsed or Refractory B-Cell Malignan
 cies\nEstimated primary completion: 2 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06634589
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944651-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281208
DTEND;VALUE=DATE:20281209
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07944651)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refra
 ctory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure\nEstim
 ated primary completion: 8 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07944651
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937124-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07937124)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: An All-Oral Combination of Ivosidenib\, Sonrotoclax\, and Chidamide for
  Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)\nEstim
 ated primary completion: 14 December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07937124
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547866-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06547866)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Study Evaluating the E
 fficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patie
 nts Previously Treated for Waldenström Macroglobulinemia\nEstimated prima
 ry completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06547866
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774234-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07774234)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Sonrotoclax\, Glofitam
 ab\, Gemcitabine\, and Oxaliplatin for Relapsed or Refractory Large B-Cell
  Lymphoma\nEstimated primary completion: 31 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07774234
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899398-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07899398)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted 
 Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-
 limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Tre
 atment-naïve CLL\nEstimated primary completion: 1 January 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07899398
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859008-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1 readout est. (NCT06859008)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1\, Mantle Cell Lymphoma.\nStudy:
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underre
 presented Ethnic and Racial Minorities With Relapsed or Refractory B-cell 
 Non-Hodgkin Lymphoma\nEstimated primary completion: 31 January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06859008
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548255-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Beqalzi (Sonrotoclax): Phase 1 readout est. (NCT07548255)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1\, Mantle Cell Lymphoma.\nStudy:
  The Efficacy and Safety of Sonrotoclax\, Zanubrutinib Combined With Obinu
 tuzumab in MCL\nEstimated primary completion: 1 March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07548255
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757672-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07757672)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: Salvage Chemotherapy With Sonrotoclax\, Cladribine\, and Standard-dos
 e Cytarabine\, Sequentially Followed by HSCT for R/R AML.\nEstimated prima
 ry completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07757672
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06943872)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Progression-Free Survival With Sonrotoclax
  Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax 
 Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chron
 ic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEsti
 mated primary completion: 30 September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854003-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06854003)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  BRAZAN: A Randomized Phase 2 Study of Bendamustine\, Rituximab\, Cytarabi
 ne (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Ri
 tuximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lympho
 ma\nEstimated primary completion: 1 November 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06854003
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Mantle Cell Lymphoma.\nStud
 y: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) Whe
 n Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEstim
 ated primary completion: 30 November 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341191-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07341191)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle
  Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy\nEstimated 
 primary completion: 31 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07341191
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682415-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07682415)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2.\nStudy: Zanubrutinib Induction
  Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/S
 LL：Stop Trial 2.0\nEstimated primary completion: 31 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07682415
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06367374-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06367374)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SL
 L\nEstimated primary completion: 28 February 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06367374
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refra
 ctory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia\nEsti
 mated primary completion: 30 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07770698
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277231-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT07277231)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib 
 (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Prev
 iously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completio
 n: February 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/son
 rotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07277231
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887061-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07887061)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Tacabrutideg and Sonrotoclax\, With Response-Guided Obinutuzumab\
 , for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocyti
 c Lymphoma (SLL)\nEstimated primary completion: 1 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07887061
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508995-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07508995)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 
 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatmen
 t-Naive Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: 
 1 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07508995
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073821-2909@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06073821)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Com
 pared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: February 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06073821
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
